Edwards Lifesciences Corporation (VIE:EWLS)
Austria · Delayed Price · Currency is EUR | Market Cap | 43.36B +12.4% |
| Revenue (ttm) | 5.70B +14.6% |
| Net Income | 879.59M -75.8% |
| EPS | 1.50 -75.5% |
| Shares Out | n/a |
| PE Ratio | 49.30 |
| Forward PE | 26.91 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 76.52 |
| Previous Close | 77.34 |
| Day's Range | 73.80 - 76.52 |
| 52-Week Range | 61.81 - 83.40 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 4, 2026 |
About Edwards Lifesciences
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aor... [Read more]
Financial Performance
In 2025, Edwards Lifesciences's revenue was $6.07 billion, an increase of 11.55% compared to the previous year's $5.44 billion. Earnings were $1.07 billion, a decrease of -74.28%.
Financial numbers in USD Financial StatementsNews
Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended Sept. 30, 2026 after the market closes on Wednesday, Nov. 4, and will hos...
Edwards Lifesciences initiated with an Overweight at Barclays
Barclays analyst Christopher Pasquale initiated coverage of Edwards Lifesciences (EW) with an Overweight rating and $110 price target The firm rolled out coverage of the medical suppliers and devices ...
Citi opens ‘upside 90-day catalyst watch’ on Edwards Lifesciences
Citi opened an “upside 90-day catalyst watch” on Edwards Lifesciences (EW) while keeping a Buy rating on the shares with a $110 price target Citi expects the company’s two trial…
Edwards Lifesciences to Host Investor Event in Conjunction With TCT
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that it will host an investor event in conjunction with the TCT annual scientific symposium in San Diego on Monday, Nov...
Edwards Lifesciences receives FDA approval for AUTUS valve
Edwards Lifesciences (EW) “announced that the U.S. Food and Drug Administration has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary valve designed specifically for pediatric patients wi...
Edwards Lifesciences Receives FDA Approval for AUTUS Valve, the First Surgical Pulmonary Valve for Pediatric Patients
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced that the U.S. Food and Drug Administration (FDA) has approved the AUTUS Size-Adjustable Valve, a surgical pulmonary val...
Edwards Lifesciences Transcript: Deutsche Bank 2026 Healthcare Summit
The summit highlighted a clear focus on structural heart disease, with regulatory changes expanding TAVR access and multi-year growth opportunities. Innovation in product lines and clinical trials, especially in TMTT, supports ambitious revenue targets, while disciplined capital allocation and global expansion remain priorities.
Edwards Lifesciences comments on TAVR national coverage decision
Edwards Lifesciences (EW) issued a statement in response to the national coverage determination, or NCD, for transcatheter aortic valve replacement, or TAVR, released by the Centers for Medicare & Med...
Edwards Lifesciences Comments on TAVR National Coverage Decision
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today issued the following statement in response to the national coverage determination (NCD) for transcatheter aortic valve replacemen...
Did Edwards Lifesciences Corporation Insiders Breach their Fiduciary Duties to Shareholders?
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible...
Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
IRVINE, Calif.--(BUSINESS WIRE)--Edwards Lifesciences Corporation (NYSE: EW) will participate in the Deutsche Bank Healthcare Summit on Wednesday, Sept. 16, 2026.Bernard Zovighian, chief executive off...
Edwards Lifesciences management to meet with Piper Sandler
Meeting to be held on September 2 hosted by Piper Sandler.
Edwards Lifesciences upgraded to Buy from Neutral at UBS
UBS upgraded Edwards Lifesciences (EW) to Buy from Neutral with a price target of $110, up from $90, after assuming coverage of the name. Edwards Lifesciences is entering a new…
Edwards Lifesciences price target raised to $105 from $100 at JPMorgan
JPMorgan raised the firm’s price target on Edwards Lifesciences (EW) to $105 from $100 and keeps an Overweight rating on the shares.
Leerink upgrades Edwards Lifesciences to Outperform, raises target to $101
As previously reported, Leerink upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a price target of $101, up from $87. The firm says it has seen “enough to…
Edwards Lifesciences price target raised to $101 from $100 at Piper Sandler
Piper Sandler raised the firm’s price target on Edwards Lifesciences (EW) to $101 from $100 and keeps an Overweight rating on the shares. The firm notes the company reported strong…
Edwards Lifesciences upgraded to Outperform from Market Perform at Leerink
Leerink analyst Mike Kratky upgraded Edwards Lifesciences (EW) to Outperform from Market Perform with a $101 price target
Edwards Lifesciences beats quarterly estimates on strong demand for heart devices
Edwards Lifesciences beat analysts' estimates for second-quarter profit and revenue on Thursday, helped by strong demand for its artificial heart valves used in complex cardiac procedures, sending i...
Edwards Lifesciences Narrows Full-Year Sales Outlook After Second-Quarter Growth
The medical-technology company said it now expects sales of $6.6 billion to $6.9 billion for the full year, raising the bottom end of its prior range of $6.5 billion to $6.9 billion.
Edwards Lifesciences Earnings Call Transcript: Q2 2026
Q2 sales grew 12.5% year-over-year, driven by strong TAVR and TMTT performance, leading to raised 2026 sales guidance and reaffirmed EPS outlook. Robust adoption of innovative therapies and favorable market dynamics support confidence in long-term 10% average sales growth.
Edwards Lifesciences Earnings release: Q2 2026
Edwards Lifesciences released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.
Edwards Lifesciences Quarterly report: Q2 2026
Edwards Lifesciences has published its Q2 2026 quarterly earnings report on July 23, 2026.
Edwards Lifesciences reports Q2 EPS 78c, consensus 74c
Reports Q2 revenue $1.74B, consensus $1.70B. In the second quarter, the company reported TAVR sales of $1.3 billion, which grew 11.3% compared to the prior year, or 10.5% on a…
Edwards Lifesciences sees Q3 EPS 71c-77c, consensus 75c
Sees Q3 revenue $1.63B-$1.71B, consensus $1.69B
Edwards Lifesciences affirms FY26 EPS view of $2.95-$3.05, consensus $3.01
Narrows higher FY26 revenue growth view to 10%-11% from 9%-11%, consensus $6.74B. The company states: “Based on the company’s second quarter performance, Edwards is increasing its full-year 2026 sales...